• Z Raykov and J Rommelaere.
• Infection and Cancer Program, Abt. F010 and INSERM U701, German Cancer Research Centre, Heidelberg, Germany. z.raykov@dkfz.de
• Gene Ther. 2008 May 1; 15 (10): 704-10.

AbstractAutologous or allogenic tumour cells have long been used in the fight against cancer as vaccines to awaken the patient's immune system. On the other hand, oncolytic viruses have emerged in recent years as powerful therapeutic tools for selectively killing tumour cells. Yet despite recent improvements in virus production, administration and targeting, the latter strategy remains limited by poor access of oncolytic viruses to primary and metastatic tumour cells. The present review focuses on how to overcome these limitations on oncolytic virus delivery, at least in part, through the use of tumour-derived or in vitro transformed carrier cells. On the basis of existing evidence, novel strategies are proposed for using such cell vehicles, alone or in combination, both as virus factories and as anticancer vaccines.

16 keywords...

hide…